Literature DB >> 31862556

Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.

Lindsey R Hammerslag1, Rebecca S Hofford1, Qiwen Kang2, Richard J Kryscio2, Joshua S Beckmann1, Michael T Bardo3.   

Abstract

BACKGROUND: Individuals with opioid use disorder (OUD) exhibit high levels of economic demand for opioids, with high levels of consumption and relative insensitivity to changes in price. Because the medications used to treat OUD in medication-assisted therapy (MAT) act as antagonists or agonists at μ opioid receptors, they may alter the relationship between price and opioid intake.
METHODS: This study examined demand for a commonly abused synthetic prescription opioid, fentanyl, in male rats following s.c. pre-treatment with naltrexone (0.1-1.0 mg/kg), morphine (0.3-3.0 mg/kg) or buprenorphine (0.3-3.0 mg/kg). We normalized demand curves to intake at the lowest price and estimated effects on elasticity (sensitivity to changes in price). Rats were first trained to earn fentanyl (5 μg/kg/infusion) on a fixed ratio schedule, then they underwent daily training under a threshold procedure designed to produce within-session demand curve estimates. Rats received 14 threshold sessions before undergoing a series of tests encompassing each drug, at each dose.
RESULTS: Elasticity was increased by pretreatment with naltrexone, morphine or buprenorphine. Morphine also decreased initial intake, when the price for fentanyl was lowest. In contrast, initial intake was increased by naltrexone (according to an inverted-U shaped curve). The effects of naltrexone did not persist after the test session, but morphine and buprenorphine continued affecting demand elasticity 24 h or 48 h after the test, respectively.
CONCLUSIONS: These results indicate that fentanyl demand is sensitive to blockade or activation of opioid receptors by the drug classes used for MAT in humans.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Behavioral economics; Buprenorphine; Demand; Fentanyl; MAT; Morphine; Naltrexone

Mesh:

Substances:

Year:  2019        PMID: 31862556      PMCID: PMC6981050          DOI: 10.1016/j.drugalcdep.2019.107804

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  58 in total

1.  Economic demand and essential value.

Authors:  Steven R Hursh; Alan Silberberg
Journal:  Psychol Rev       Date:  2008-01       Impact factor: 8.934

2.  Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.

Authors:  Megan J Moerke; S Stevens Negus
Journal:  Neuropharmacology       Date:  2019-03-14       Impact factor: 5.250

3.  Behavioral activating effects of opiates and opioid peptides.

Authors:  R G Browne; D S Segal
Journal:  Biol Psychiatry       Date:  1980-02       Impact factor: 13.382

Review 4.  Hot topics in opioid pharmacology: mixed and biased opioids.

Authors:  Ammar A H Azzam; John McDonald; David G Lambert
Journal:  Br J Anaesth       Date:  2019-04-19       Impact factor: 9.166

5.  A critical transition in cocaine self-administration: behavioral and neurobiological implications.

Authors:  Amandine Zittel-Lazarini; Martine Cador; Serge H Ahmed
Journal:  Psychopharmacology (Berl)       Date:  2007-02-21       Impact factor: 4.530

6.  Reliability and validity of a demand curve measure of alcohol reinforcement.

Authors:  James G Murphy; James MacKillop; Jessica R Skidmore; Ashley A Pederson
Journal:  Exp Clin Psychopharmacol       Date:  2009-12       Impact factor: 3.157

7.  Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil.

Authors:  Kirsten A Porter-Stransky; Brandon S Bentzley; Gary Aston-Jones
Journal:  Addict Biol       Date:  2015-11-24       Impact factor: 4.280

8.  Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice.

Authors:  Tannia S Clark; David D Clark; Robert F Hoyt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

9.  Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.

Authors:  Paul Glue; Gavin Cape; Donna Tunnicliff; Michelle Lockhart; Fred Lam; Andrew Gray; Noelyn Hung; C Tak Hung; Sarah Harland; Jane Devane; John Howes; Holger Weis; Lawrence Friedhoff
Journal:  J Clin Pharmacol       Date:  2016-02-29       Impact factor: 3.126

10.  The influence of sex and estrous cyclicity on cocaine and remifentanil demand in rats.

Authors:  Ryan T Lacy; Bridget P Austin; Justin C Strickland
Journal:  Addict Biol       Date:  2019-02-19       Impact factor: 4.280

View more
  5 in total

1.  Effects of NMDA receptor antagonists on behavioral economic indices of cocaine self-administration.

Authors:  Matthew J Horchar; Joy L Kappesser; Maria R Broderick; Makayla R Wright; Justin R Yates
Journal:  Drug Alcohol Depend       Date:  2022-02-12       Impact factor: 4.492

2.  Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.

Authors:  E Andrew Townsend; Bruce E Blough; David H Epstein; S Stevens Negus; Yavin Shaham; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2022-07-29       Impact factor: 8.294

Review 3.  The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.

Authors:  Colleen G Jordan; Amy L Kennalley; Alivia L Roberts; Kaitlyn M Nemes; Tenzing Dolma; Brian J Piper
Journal:  Pharmacy (Basel)       Date:  2022-04-19

4.  Demand for fentanyl becomes inelastic following extended access to fentanyl vapor self-administration.

Authors:  Sam A McConnell; Adam J Brandner; Brandon A Blank; David N Kearns; George F Koob; Leandro F Vendruscolo; Brendan J Tunstall
Journal:  Neuropharmacology       Date:  2020-10-20       Impact factor: 5.250

5.  A drug-vs-food "choice" self-administration procedure in rats to investigate pharmacological and environmental mechanisms of substance use disorders.

Authors:  E Andrew Townsend; Kathryn L Schwienteck; Hannah L Robinson; Stephen T Lawson; Matthew L Banks
Journal:  J Neurosci Methods       Date:  2021-03-08       Impact factor: 2.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.